Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Point-of-care molecular diagnosis of Mycoplasma pneumoniae including macrolide sensitivity using quenching probe polymerase chain reaction
Title: | Point-of-care molecular diagnosis of Mycoplasma pneumoniae including macrolide sensitivity using quenching probe polymerase chain reaction |
Authors: | Ishiguro, Nobuhisa Browse this author →KAKEN DB | Sato, Rikako Browse this author | Mori, Toshihiko Browse this author | Tanaka, Hiroshi Browse this author | Narita, Mitsuo Browse this author | Nagano, Takashi Browse this author | Owaku, Masato Browse this author | Miyajima, Kensuke Browse this author | Manabe, Atsushi Browse this author →KAKEN DB |
Issue Date: | 28-Jan-2022 |
Publisher: | PLOS |
Journal Title: | PLoS ONE |
Volume: | 16 |
Issue: | 10 |
Start Page: | e0258694 |
Publisher DOI: | 10.1371/journal.pone.0258694 |
Abstract: | Objectives Macrolides are generally considered to be the drugs of choice for treatment of patients with Mycoplasma pneumoniae infection. However, macrolide-resistant M. pneumoniae has been emerging since about 2000. The Smart Gene system (MIZUHO MEDY Co., Ltd., Tosu, Japan) is a novel fully automated system for detection of pathogens using the method of quantitative polymerase chain reaction (qPCR) with QProbe (QProbe PCR). The entire procedure is completed within 50 min and the size of the instrument is small (15 x 34 x 30 cm). The purpose of this study was to evaluate the usefulness of the Smart Gene system for detection of M. pneumoniae and detection of a point mutation at domain V of the 23S rRNA gene of M. pneumoniae. Materials Pharyngeal swab samples were collected from 154 patients who were suspected of having respiratory tract infections associated with M. pneumoniae. Results Compared with the results of qPCR, the sensitivity and specificity of the Smart Gene system were 98.7% (78/79) and 100.0% (75/75), respectively. A point mutation at domain V of the 23S rRNA gene was detected from 7 (9.0%) of 78 M. pneumoniae-positive samples by the Smart Gene system and these results were confirmed by direct sequencing. The minimum inhibitory concentrations of clarithromycin among the 5 isolates of M. pneumoniae with a point mutation at domain V of the 23S rRNA gene were >64 mu g/ml and those among the 33 isolates without a mutation in the 23S rRNA gene were Conclusion The Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. |
Type: | article |
URI: | http://hdl.handle.net/2115/83947 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|